Principia Biopharma Inc.
DelistedCIK 1510487fmd_1V75KHVSVKT76X0WES5ZJJ4J43Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2016 to Jun 30, 2020, 15 periods
Latest annual · FY2019
Millions- Total revenues
- 35
- Operating income
- (59)
- Net income
- 18
- Free cash flow
- (45)
Latest quarter · Q2 FY2020
Millions- Total revenues
- 50
- Operating income
- 10
- Net income
- 11
- Free cash flow
- (27)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2016 to FY2019
- n/m
Principia Biopharma Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2019 | FY2018 | Change | Source |
|---|---|---|---|---|
| Revenue | $35.2 million | $69.1 million | -49.1% | 10-K 2020-03-10 · proof |
| Operating income | -$58.8 million | $17.1 million | -442.8% | 10-K 2020-03-10 · proof |
| Cash from operating activities | -$42.5 million | -$21.2 million | 10-K 2020-03-10 · proof | |
| Free cash flow | -$44.7 million | -$22.2 million | 10-K 2020-03-10 · proof | |
| Total assets | $382.7 million | $195.5 million | +95.8% | 10-K 2020-03-10 · proof |
| Total liabilities | $23.8 million | $25.7 million | -7.4% | 10-K 2020-03-10 · proof |
| Cash and cash equivalents | $39.5 million | $34.5 million | +14.6% | 10-K 2020-03-10 · proof |
- What was Principia Biopharma Inc.'s revenue in fiscal 2019?
- Principia Biopharma Inc. reported revenue of $35.2 million for fiscal 2019 (the year ended Dec 31, 2019), against $69.1 million the year before (-49.1%). Source: the 10-K filed with the SEC on Mar 10, 2020. SEC
- What was Principia Biopharma Inc.'s operating income in fiscal 2019?
- Principia Biopharma Inc. reported operating income of -$58.8 million for fiscal 2019 (the year ended Dec 31, 2019), against $17.1 million the year before (-442.8%). Source: the 10-K filed with the SEC on Mar 10, 2020. SEC
- What was Principia Biopharma Inc.'s cash from operating activities in fiscal 2019?
- Principia Biopharma Inc. reported cash from operating activities of -$42.5 million for fiscal 2019 (the year ended Dec 31, 2019), against -$21.2 million the year before. Source: the 10-K filed with the SEC on Mar 10, 2020. SEC
- What was Principia Biopharma Inc.'s free cash flow in fiscal 2019?
- Principia Biopharma Inc. reported free cash flow of -$44.7 million for fiscal 2019 (the year ended Dec 31, 2019), against -$22.2 million the year before. Source: the 10-K filed with the SEC on Mar 10, 2020. SEC
- What are Principia Biopharma Inc.'s total assets?
- As of Dec 31, 2019, Principia Biopharma Inc. reported total assets of $382.7 million, against $195.5 million a year earlier (+95.8%). Source: the 10-K filed with the SEC on Mar 10, 2020. SEC
- What are Principia Biopharma Inc.'s total liabilities?
- As of Dec 31, 2019, Principia Biopharma Inc. reported total liabilities of $23.8 million, against $25.7 million a year earlier (-7.4%). Source: the 10-K filed with the SEC on Mar 10, 2020. SEC
- What are Principia Biopharma Inc.'s cash and cash equivalents?
- As of Dec 31, 2019, Principia Biopharma Inc. reported cash and cash equivalents of $39.5 million, against $34.5 million a year earlier (+14.6%). Source: the 10-K filed with the SEC on Mar 10, 2020. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1510487&period_type=annual&limit=5"Information only, not investment advice.